Kuvaus

Proactive: Prospective pioglitazone clinical trial in macrovascular events a macrovascular outcome study in type 2 diabetic patients comparing pioglitazone with placebo in addition to existing therapy.

Director of research: Tuomilehto Jaakko, Professor of Public Health

A macrovascular outcome study in type 2 diabetic patients comparing pioglitazone with placebo in addition to existing therapy.


The aim of the study is to evaluate the efficacy, safety and tolerability of tesaglitazar therapy when added to the therapy of patients with type 2 Diabetes poorly controlled on metformin alone Gallant 5.

TilaPäättynyt
Todellinen alku/loppupvm01/01/200231/12/2015

Rahoitus

  • Takeda: 135 965,00 €

Tieteenalat

  • 3142 Kansanterveystiede, ympäristö ja työterveys